Compare Atlassian Corporation PLC (TEAM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Atlassian Corporation PLC trades at $90.53 (market cap $23.67B), while State Street SPDR S&P Biotech ETF trades at $154.41. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| TEAM | XBI | |
|---|---|---|
Market Cap | $23.67B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $203.00 | $164.28 |
52-Week Low | $57.15 | $85.16 |
Enterprise Value | $23.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $90.60, down 2.88% on the day, with a bullish technical signal from moving averages and strong analyst support (67% buy ratings). The company shows accelerating revenue growth, reaching $5.22B in 2025, and has beaten earnings estimates for three consecutive quarters. Recent news highlights AI-driven product enhancements and enterprise adoption momentum, with the Service Collection surpassing $1B in annual recurring revenue.
TEAM presents a growth investment case with a consensus price target of $114.54 (26% upside), supported by cloud momentum and AI integration. However, persistent net losses (-$256.69M in 2025) and high valuation multiples (P/S 3.96, P/B 26.93) pose risks amid competitive pressures and macroeconomic sensitivity in software spending.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
